Magic of the Mushrooms: Effects of Psilocybin Decriminalization.

LSD MDMA Psilocybin reforms policy change psychedelics

Journal

Journal of psychoactive drugs
ISSN: 2159-9777
Titre abrégé: J Psychoactive Drugs
Pays: United States
ID NLM: 8113536

Informations de publication

Date de publication:
10 Jul 2024
Historique:
medline: 10 7 2024
pubmed: 10 7 2024
entrez: 10 7 2024
Statut: aheadofprint

Résumé

In the past few years, psilocybin, a psychedelic compound found in "magic mushrooms" (psilocybin mushrooms), has undergone decriminalization in numerous cities across the US and has been legalized in Oregon and Colorado. Proponents of psilocybin decriminalization have emphasized its therapeutic potential in treating mental health disorders. Furthermore, psilocybin mushrooms are considered the safest psychedelic option, with lower potency and a reduced risk of overdoses and emergency hospitalizations compared to other prevalent psychedelics, such as LSD (lysergic acid diethylamide) and MDMA (3,4-methylenedioxymethamphetamine). We analyzed the impact of psilocybin reforms on public interest in psilocybin, as well as their cross-commodity effects on LSD and MDMA, utilizing extensive web-based search data. We observe a significant increase in psilocybin search volume and a notable reduction in search volume associated with LSD and MDMA. Our results are consistent nationwide across states, irrespective of their stance on psilocybin reforms. The shift in public interest toward psilocybin, which is considered the safest psychedelic, away from LSD and MDMA, carries positive implications for public health.

Identifiants

pubmed: 38984875
doi: 10.1080/02791072.2024.2376755
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Auteurs

Ashutosh Bhave (A)

Walton College of Business, University of Arkansas, Fayetteville, AR, USA.

Classifications MeSH